Figure 2
Figure 2. Inhibition of CD8+ T cell-mediated GVHD by anti-OPN Ab. Lethally irradiated B6/SJL recipient mice were injected with C3H.SW CD8+ T cells plus C3H.SW TCD BM or C3H.SW TCD BM alone. These recipients were treated with anti-OPN Ab or control IgG (200 μg/mouse) at days 0, 3, 6, 10, and 14 after transplantation. (A) Survival and clinical GVHD signs were monitored over time after transplantation. Symbols are as follows: (▴), TCD BM alone; (■), TCD BM plus CD8+ T cells plus control IgG treatment; and (○), TCD BM plus CD8+ T cells plus anti-OPN Ab treatment; n = 12 for each group. (B) These murine livers and intestines were collected at day 35 after the aforementioned transplantation and were sectioned for histologic examination with hematoxylin and eosin and substantially semiquantitative histopathology scoring; original magnification: × 200; n = 6 for each group. Samples were visualized with a Nikon Eclipse 80i microscope equipped with Nikon 20×/0.75 PLAN Apo objective and Nikon DXM1200F digital camera. Nikon ACT-1 software Version 2.63 was used to acquire images and Adobe Photoshop 7.0 software was used to manipulate images. (C) Splenocytes (5 × 107) of DBA/2 mice were injected intravenously into sublethally irradiated (6.5 Gy) BALB/c recipient mice accompanied by DBA/2 TCD BM (1 × 107). These recipients were treated with anti-OPN Ab or control IgG (200 μg/mouse) at days 0, 3, 6, 10, and 14 after transplantation. The recipients were monitored for survival (n = 12 per group) and symptom of proteinuria (n = 6 per group). Symbols are as follows: ( × ), irradiation only; (▴), TCD BM alone; (■), TCD BM plus splenocytes plus control IgG treatment; and (○), TCD BM plus splenocytes plus anti-OPN treatment. Results were representative of 3 independent experiments. *P < .05.

Inhibition of CD8+ T cell-mediated GVHD by anti-OPN Ab. Lethally irradiated B6/SJL recipient mice were injected with C3H.SW CD8+ T cells plus C3H.SW TCD BM or C3H.SW TCD BM alone. These recipients were treated with anti-OPN Ab or control IgG (200 μg/mouse) at days 0, 3, 6, 10, and 14 after transplantation. (A) Survival and clinical GVHD signs were monitored over time after transplantation. Symbols are as follows: (▴), TCD BM alone; (■), TCD BM plus CD8+ T cells plus control IgG treatment; and (○), TCD BM plus CD8+ T cells plus anti-OPN Ab treatment; n = 12 for each group. (B) These murine livers and intestines were collected at day 35 after the aforementioned transplantation and were sectioned for histologic examination with hematoxylin and eosin and substantially semiquantitative histopathology scoring; original magnification: × 200; n = 6 for each group. Samples were visualized with a Nikon Eclipse 80i microscope equipped with Nikon 20×/0.75 PLAN Apo objective and Nikon DXM1200F digital camera. Nikon ACT-1 software Version 2.63 was used to acquire images and Adobe Photoshop 7.0 software was used to manipulate images. (C) Splenocytes (5 × 107) of DBA/2 mice were injected intravenously into sublethally irradiated (6.5 Gy) BALB/c recipient mice accompanied by DBA/2 TCD BM (1 × 107). These recipients were treated with anti-OPN Ab or control IgG (200 μg/mouse) at days 0, 3, 6, 10, and 14 after transplantation. The recipients were monitored for survival (n = 12 per group) and symptom of proteinuria (n = 6 per group). Symbols are as follows: ( × ), irradiation only; (▴), TCD BM alone; (■), TCD BM plus splenocytes plus control IgG treatment; and (○), TCD BM plus splenocytes plus anti-OPN treatment. Results were representative of 3 independent experiments. *P < .05.

Close Modal

or Create an Account

Close Modal
Close Modal